CD274 and medullary thyroid gland carcinoma: Another case report also described a patient with MTC already treated with sunitinib and, having undergone a 3-month trial with the GI-6207 cancer vaccine, was enrolled in a phase 1 trial with the PD-L1 inhibitor avelumab (NCT01772004).